Case Reports
Successful benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis
N. Belfeki1, S. Abroug2, N. Ghriss3, I. Chouchane4, S. Hamrouni5, A. Strazzulla6, S. Zayet7
- Department of Internal Medicine, Groupe Hospitalier Sud Ile de France, Melun, France. nabil.belfeki@ghsif.fr
- Department of Internal Medicine, Groupe Hospitalier Sud Ile de France, Melun, France.
- Department of Internal Medicine, Groupe Hospitalier Sud Ile de France, Melun, France.
- Department of Radiology, Groupe Hospitalier Sud Ile de France, Melun, France.
- Department of Internal Medicine, Groupe Hospitalier Sud Ile de France, Melun, France.
- Department of Internal Medicine, Groupe Hospitalier Sud Ile de France, Melun, France.
- Department of Infectious Diseases, Nord Franche-Comté Hospital, Trévenans, France. souhail.zayet@gmail.com
CER15248
2022 Vol.40, N°4
PI 0834, PF 0837
Case Reports
Free to view
(click on article PDF icon to read the article)
PMID: 35522541 [PubMed]
Received: 14/10/2021
Accepted : 10/01/2022
In Press: 04/05/2022
Published: 11/05/2022
Abstract
Eosinophilic granulomatosis with polyangiitis (EGPA) is characterised by many features, including asthma, allergic rhinitis, peripheral and tissue eosinophilia, and vasculitis. Its pathophysiology is still unclear and we suggest that there are different phenotypes of EGPA, which may respond differently to available treatments. Within the most promising targeting biotherapy, benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, has proved both highly effective and safe. We report herewith a case of EGPA presenting a myocarditis relapse successfully treated with benralizumab.
